肿瘤放射治疗增敏剂研究新进展

Radiosensitizers development and the pathways

  • 摘要: 目前除传统的亲电子放射增敏剂硝基咪唑类、硝基苯等之外,还发现了部分化疗药物也具有肿瘤放射治疗增敏效果。分子靶向药物的研究方兴未艾,分别作用于组蛋白去乙酰化酶、信号转导子和转录激活因子3、聚腺苷二磷酸核糖基聚合酶、前列腺素H合成酶2、缺氧诱导因子1、核转录因子、热休克蛋白、毛细血管扩张共济失调突变基因等分子靶点,通过各种不同的途径干扰肿瘤DNA修复、抑制肿瘤细胞增殖、促进其凋亡、抑制血管生成从而达到放射增敏效果。

     

    Abstract: Except for the traditional radiotherapy sensitization agents such as nitro imidazoles and nitrobenzene, some chemotherapeutics also showed sensitization effect. Molecular targeted drug research is in the ascendant, respectively interacting with histone deacetylase, signal transducer and activator of transcription 3, poly(adenosine diphosphate-ribose)polymerase, prostaglandin H synthase-2, (hypoxia inducible factor-1, nuclear factor kappa-light-chain-enhancer of activated B cells, heat shock protein, ataxia-telangiectasia mutated gene and so on, through various ways such as interfering DNA repair, inhibiting tumor cell proliferation, promoting tumor cell apoptosis and inhibiting angiogenesis to improve the sensitivity of cancer cells to iron radiation.

     

/

返回文章
返回